




Forskningsrapport DLCG, DLCR 2025-26 & Dansk Forskningscenter for Lungekræft

Ole Hilberg, Professor i lungemedicin ved SDU,
formand for forskning i DLCG

Lung cancer DK 2016-26

Documents by year

Scopus




Copyright © 2026 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

Lung cancer 2016-26, Nordics

Documents by country or territory

Scopus

Compare the document counts for up to 15 countries/territories.




Copyright © 2026 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

Lung cancer 2025-26, authors

Documents by author

Compare the document counts for up to 15 authors.

Scopus




Copyright © 2026 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

Lung cancer
2025-2026,
collab.

Documents by country or territory

Scopus

Compare the document counts for up to 15 countries/territories.




Copyright © 2026 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

Lung cancer 2025-26, fund.

Documents by funding sponsor

Scopus

Compare the document counts for up to 15 funding sponsors.




Copyright © 2026 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

Lung cancer subject

Documents by subject area

Scopus



Citations (25-26) > 15

316

© 2025 by The Society of Thoracic Surgeons
Published by Elsevier Inc.

0003-4975/\$36.00

<https://doi.org/10.1016/j.athoracsur.2024.07.012>

Lung: Research

Impact of Margin Distance on Locoregional Recurrence and Survival After Thoracoscopic Segmentectomy



Lin Huang, MD, PhD,¹ and René Horsleben Petersen, MD, PhD¹

ABSTRACT

BACKGROUND This study aimed to identify the impact of margin distance on locoregional recurrence (LRR) and survival outcomes after thoracoscopic segmentectomy for non-small cell lung cancer.

Citations (25-26) > 15



Contents lists available at [ScienceDirect](#)

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com



Original Article

Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: An ESTRO clinical practice guideline

Dirk De Ruyscher^{a,b,*}, Els Wauters^c, Verena Jendrossek^d, Andrea Riccardo Filippi^{e,f}, Marie-Pierre Revel^{g,h}, Corinne Faivre-Finnⁱ, Jarushka Naidoo^{j,k}, Sara Ramella^l, Matthias Guckenberger^l, Umberto Ricardi^m, Azza Khalil^{n,o}, Marieke Schor^p, Valentina Bartolomeo^{a,b,q,r}, Paul Martin Putora^{s,t}



Citations (25-26) > 15

ORIGINAL ARTICLE



RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, *EGFR*-Mutated Metastatic NSCLC



Kazuhiko Nakagawa, MD, PhD,^{a,*} Edward B. Garon, MD, MS,^b Takashi Seto, MD, PhD,^c Makoto Nishio, MD, PhD,^d Santiago Ponce Aix, MD,^e Luis Paz-Ares, MD, PhD,^e Chao-Hua Chiu, MD,^f Keunchil Park, MD, PhD,^{g,1} Silvia Novello, MD, PhD,^h Ernest Nadal, MD, PhD,ⁱ Kazumi Nishino, MD, PhD,^j Kiyotaka Yoh, MD,^k Jin-Yuan Shih, MD, PhD,^l Jeannie Y. K. Chik, M.B.B.S.,^m Denis Moro-Sibilot, MD, PhD,ⁿ Tarun Puri, MD,^o Sunoj Chacko Varughese, MSc,^p Bente Frimodt-Moller, MSc,^q Carla Visseren-Grul, MD,^r Martin Reck, MD, PhD^s

Citations (25-26) > 15



ORIGINAL ARTICLE

Savolitinib plus osimertinib in epidermal growth factor receptor (*EGFR*)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study

F. de Marinis^{1*}, T. M. Kim², L. Bonanno^{3,4}, S. Cheng⁵, S.-W. Kim⁶, M. Tiseo^{7,8}, Q. Chu⁹, C. Proto¹⁰, A. Sacher^{11,12,13}, Y.-H. Luo^{14,15}, S. Novello¹⁶, D. Hao^{17,18}, C. Baik¹⁹, L. Bazhenova²⁰, J. S. Lee²¹, B. C. Cho²², J. Cadranet²³, T. B. Diep²⁴, G. Metro²⁵, P. Narayanan²⁶, Y. Yoneshima²⁷, J. de Castro Carpeño²⁸, C. Baldotto²⁹, C. Nyhus³⁰, J. C.-H. Yang³¹, L. V. Sequist³², B. Levy³³, R. Hartmaier³⁴, I. Igwegbe³⁵, L. Poole³⁶, W. Xu³⁷ & M.-J. Ahn^{38*}

Citations (25-26) > 15

Clinical Trial Updates



⑥ Selpercatinib in *RET* Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial

Oliver Gautschi, MD¹; Keunchil Park, MD, PhD^{2,3}; Benjamin J. Solomon, MBBS, PhD⁴ ; Pascale Tomasini, MD⁵; Herbert H. Loong, MBBS⁶ ; Filippo De Braud, MD⁷; Koichi Goto, MD, PhD⁸ ; Patrick Peterson, PhD⁹; Scott Barker, PhD⁹ ; Katherine Liming, BSc⁹; Geoffrey R. Oxnard, MD⁹ ; Bente Frimodt-Moller, MSc¹⁰; and Alexander Drilon, MD¹¹

DOI <https://doi.org/10.1200/JCO-24-02076>

Citations (25-26) > 15

JACC: CARDIOONCOLOGY

VOL. 7, NO. 4, 2025

© 2025 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

ORIGINAL RESEARCH

Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment



A Population-Based Cohort Study

Frits I. Mulder, MD,^{a,b,c} Erzsébet Horváth-Puhó, PhD,^{c,d} Nick van Es, MD,^a Lars Pedersen, PhD,^{c,d} Harry R. Büller, PhD,^a Deirdre Cronin-Fenton, PhD,^{c,d} Christian F. Christiansen, MD, PhD,^{c,d} Hans Erik Bøtker, MD, PhD,^e Krishnan Bhaskaran, PhD,^f Henrik T. Sørensen, MD, PhD^{c,d}

Citations (25-26) > 15

nature medicine



Brief Communication

<https://doi.org/10.1038/s41591-024-03216-y>

Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma

Received: 21 September 2023

Accepted: 29 July 2024

Published online: 13 January 2025

Check for updates

James R. M. Black^{1,2,112}, Gabor Bartha^{3,112}, Charles W. Abbott³, Sean M. Boyle³, Takahiro Karasaki^{1,2,4,5}, Bailiang Li³, Rui Chen³, Jason Harris³, Selvaraju Veeriah¹, Martina Colopi¹, Maise Al Bakir^{1,2}, Wing Kin Liu¹, John Lyle³, Fábio C. P. Navarro³, Josette Northcott³, Rachel Marty Pyke³, Mark S. Hill^{1,2}, Kerstin Thol^{1,6}, Ariana Huebner^{1,2,6}, Chris Bailey^{1,2}, Emma C. Colliver^{1,2}, Carlos Martínez-Ruiz^{1,6}, Kristiana Grigoriadis^{1,2,6}, Piotr Pawlik^{1,6}, David A. Moore^{1,2,7}, Daniele Marinelli^{1,6,8}, Oliver G. Shutkever¹, Cian Murphy^{1,2}, Monica Sivakumar¹, TRACERx consortium*, Jacqui A. Shaw⁹, Allan Hackshaw¹⁰, Nicholas McGranahan^{1,6}, Mariam Jamal-Hanjani^{1,4,11}, Alexander M. Frankell^{1,2}, Richard O. Chen^{3,113} & Charles Swanton^{1,2,11,113}✉

Citations (25-26) > 15

Rheumatology, 2025, **64**, 1019–1028
<https://doi.org/10.1093/rheumatology/keae140>
Advance access publication 7 March 2024
Original Article



British Society for
Rheumatology

RHEUMATOLOGY

OXFORD

Clinical science

Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study

Rasmus Westermann ^{1,2,*}, **René Lindholm Cordtz**¹, **Kirsten Duch**^{1,3}, **Lene Mellemkjaer** ⁴,
Merete Lund Hetland ^{5,6,7}, **Bergur Magnussen**¹, **Lene Dreyer**¹

¹Center of Rheumatic Research Aalborg (CERRA), Department of Rheumatology, Aalborg University Hospital, Aalborg University, Aalborg, Denmark

²Clinical Cancer Research Unit, Aalborg University Hospital, Aalborg, Denmark

³Research Data and Biostatistics, Aalborg University Hospital, Aalborg, Denmark

⁴Danish Cancer Society Institute, Copenhagen, Denmark

⁵The DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark

⁶Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark

⁷Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark

Citations (25-26) > 15

Current Oncology Reports (2025) 27:45–58
<https://doi.org/10.1007/s11912-024-01622-6>

REVIEW



Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials

Lone Gamrath¹ · Tobias Bruun Pedersen² · Martin Vad Møller² · Lone Marie Volmer^{1,3} · Linda Holst-Christensen¹ · Lene Weber Vestermark¹ · Frede Donskov^{1,4}

Accepted: 9 November 2024 / Published online: 2 January 2025

Citations (25-26) > 15

CDD*press*

www.nature.com/cdd

ARTICLE OPEN

 Check for updates

Polyol pathway-generated fructose is indispensable for growth and survival of non-small cell lung cancer

Annemarie Schwab^{1,2,15}, Mohammad Aarif Siddiqui^{3,15} , Vignesh Ramesh^{1,3}, Paradesi Naidu Gollavilli^{1,3}, Adriana Martinez Turtos³, Sarah Søgaard Møller³ , Luisa Pinna³, Jesper F. Havelund³, Anne Mette A. Rømer³, Pelin Gülizar Ersan^{4,5}, Beatrice Parma^{1,6}, Sabine Marschall¹, Katja Dettmer⁷, Mohammed Alhusayan^{8,9}, Pietro Bertoglio¹⁰, Giulia Querzoli^{11,12}, Dirk Mielenz¹³ , Ozgur Sahin¹⁴, Nils J. Færgeman³, Irfan A. Asangani⁸ and Paolo Ceppi^{1,3} 

Citations (25-26) > 15

nature communications



Article

<https://doi.org/10.1038/s41467-025-58248-w>

A genome-wide cross-trait analysis characterizes the shared genetic architecture between lung and gastrointestinal diseases

Received: 25 June 2024

Accepted: 11 March 2025

Published online: 28 March 2025



Check for updates

Dongfang You^{1,2,12}, Yaqian Wu^{1,12}, Mengyi Lu^{1,12}, Fang Shao¹, Yingdan Tang¹, Sisi Liu¹, Liya Liu³, Zewei Zhou⁴, Ruyang Zhang¹, Sipeng Shen¹, Theis Lange⁵, Hongyang Xu⁶, Hongxia Ma^{7,8}, Yongmei Yin², Hongbing Shen^{7,8}, Feng Chen^{1,8,9,10,13}, David C. Christiani^{11,13}, Guangfu Jin^{7,8} & Yang Zhao^{1,8,9,10}

Citations (25-26) > 15

Article

Clonal driver neoantigen loss under *EGFR* TKI and immune selection pressures

<https://doi.org/10.1038/s41586-025-08586-y>

Received: 16 December 2022

Accepted: 2 January 2025


Published online: 19 February 2025

Open access

 Check for updates


Maise Al Bakir^{1,2,25}, James L. Reading^{2,3,25}, Samuel Gamble³, Rachel Rosenthal¹, Imran Uddin⁴, Andrew Rowan¹, Joanna Przewrocka¹, Amber Rogers³, Yien Ning Sophia Wong², Amalie K. Bentzen³, Selvaraju Veeriah², Sophia Ward^{1,2,5}, Aaron T. Garnett⁶, Paula Kalavakur⁶, Carlos Martínez-Ruiz⁷, Clare Puttick^{1,2,7}, Ariana Huebner^{1,2,7}, Daniel E. Cook¹, David A. Moore^{1,2,8}, Chris Abbosh², Crispin T. Hiley^{1,2}, Cristina Naceur-Lombardelli², Thomas B. K. Watkins¹, Marina Petkovic^{9,10,11}, Roland F. Schwarz^{12,13}, Felipe Gálvez-Cancino¹⁴, Kevin Litchfield^{1,2}, Peter Meldgaard¹⁵, Boe Sandahl Sorensen¹⁶, Line Bille Madsen¹⁷, Dirk Jäger¹⁸, Martin D. Forster^{2,19}, Tobias Arkenau²⁰, Clara Domingo-Vila²¹, Timothy I. M. Tree²¹, Mohammad Kadivar²², Sine Reker Hadrup²², Benny Chain^{4,23}, Sergio A. Quezada^{2,24,26}✉, Nicholas McGranahan^{2,7,26}✉ & Charles Swanton^{1,2,26}✉

Dansk Forskningscenter for Lungekræft



- Ved Visionsmødet den 28.-29. maj 2026 blev der opnået enighed om en ny, mere fokuseret strategi.
- Da det ikke er lykkedes at opnå en større samlet fondsbevilling, skal Forskningscentret i den kommende fase koncentrere indsatsen om at understøtte udviklingen af stærke nationale projektansøgninger.
- Det blev foreslået at udbyde initieringsstøtte til 4 prædefinerede nationale projektspor samt 2 åbne/valgfrie projekter.
- Forskningscentret skal formidle kontakt, hvis flere ønsker at arbejde med samme emne. Der lægges vægt på, at projekterne er klinisk relevante, metodisk solide og realistiske at starte op med en mindre bevilling. Der skal især prioriteres projekter, som kan skaleres nationalt, anvende eksisterende data eller infrastruktur og skabe viden, der kan omsættes i klinisk praksis.

Dansk Forskningscenter for Lungekræft



4 prædefinerede nationale projektspor:

• 1. Præhabilitering ved lungekræft

Projekter, der styrker patientens fysiske, ernæringsmæssige og mentale tilstand før behandling. Der lægges vægt på objektive målinger, validerede redskaber og mulighed for national standardisering. Projekter kan eksempelvis bygge videre på et run-in setup og skal tænkes som et muligt nationalt tilbud. Forskningscentret vil koble ansøgere med relevante fagmiljøer, herunder miljøer med særlig erfaring i præhabilitering.

• 2. Tidlig opsporing og risikoprofilering

Projekter, der kan bidrage til at finde patienter tidligere i forløbet, før klassiske sene symptomer som hæmoptyse, smerter og vægttab. Der ønskes særligt fokus på reduktion af social og økonomisk ulighed, samt på anvendelse af biomarkører, big data, AI eller andre metoder til at identificere risikogrupper og oversete symptommønstre.


• 3. Risikostratificeret opfølgning og monitorering

Projekter, der udvikler eller afprøver modeller for risikostratificeret opfølgning efter kurativ behandling eller ved avanceret sygdom. Relevante elementer er prædiktionsmodeller, real world data fra store kohorter, subgruppeanalyser, MDT-data, ctDNA eller andre markører, der kan udnytte ressourcerne til de patienter, der har størst behov.

• 4. Hvad er den rette behandling?

Projekter, der undersøger individualiseret behandlingsvalg i forhold til stadie, komorbiditet, livslængde og patientpræferencer. Det kan eksempelvis omfatte kirurgi versus stereotaktisk strålebehandling, beslutningsstøtteværktøjer, stadiespecifik behandling og systematisk måling af livskvalitet som del af behandlingsvalget.

Dansk
Forskningscenter
for Lungekræft



DFLK støtter med 50.000 kr. pr. projekt

**Der ydes støtte til maksimum 6 projekter:
4 prædefinerede projektspor og 2 åbne/valgfrie projekter**

**Søgning muligt fra den 16. juni 2026 via DLCG-netværk og
DFLK-hjemmeside**

Ansøgningsfrist: 15. august 2026

**Udvalgte projekter inviteres til sparring/workshop og plan for
større fondsansøgning. Møde på Fyn den 22. oktober 2026**

Kontaktperson: Kristina Kock Hansen

E-mail: adm.lungetcancer@rsyd.dk